Key Takeaways
- • Scribe Therapeutics, co-founded by Nobel laureate Jennifer Doudna, raised approximately $129 million in its IPO, marking the first public offering for a gene-editing company in over a year and positioning itself as the 14th biotech to go public in 2026.
- • The company is listed on Nasdaq under ticker SCTX and is developing CRISPR gene-editing therapies targeting lipid disorders, specifically aiming to lower "bad cholesterol" and fatty triglycerides, with potential applications in cardiovascular disease treatment.
- • Scribe Therapeutics has secured strategic partnerships with major pharmaceutical companies including Biogen, Sanofi, and Eli Lilly, backed by more than $180 million in collaborative funding from Sanofi and Eli Lilly partnerships.
- • Jennifer Doudna's personal stake in the company could be valued at approximately $8.5 million following the IPO, while the UC Board of Regents' stake was valued at approximately $2.6 million, reflecting early academic institutional support for the nine-year-old firm founded in 2017.
- • The IPO represents a significant test of public market appetite for earlier-stage gene-editing therapeutics, occurring amid a broader biotech IPO resurgence in the second half of 2026.
Summary
Scribe Therapeutics, a nine-year-old gene-editing company co-founded by CRISPR pioneer and Nobel laureate Jennifer Doudna, completed its IPO in late July 2026, raising approximately $129 million at a valuation that positions it as a notable entrant in the therapeutic gene-editing space. The company lists on Nasdaq under the ticker symbol SCTX, marking the first public offering for a gene-editing therapeutics developer in over a year and signaling renewed institutional interest in earlier-stage biotech companies pursuing transformative genetic therapies.
The company's clinical focus centers on CRISPR-based gene-editing treatments targeting cardiovascular risk factors, with initial therapeutic candidates designed to lower low-density lipoprotein cholesterol and triglycerides. This lipid-lowering focus represents a significant commercial opportunity within cardiovascular disease prevention, a market segment dominated by traditional pharmaceutical approaches. Scribe's platform approach to genetic medicine positions it distinctly within the expanding landscape of precision therapeutics.
Scribe Therapeutics has established substantial partnership infrastructure with established pharmaceutical giants, including collaborations with Biogen, Sanofi, and Eli Lilly. These partnerships represent over $180 million in combined funding commitments, providing both validation of the platform's scientific merit and significant capital resources to advance clinical development. Such partnerships also mitigate development risk by distributing financial and regulatory burdens across experienced pharmaceutical operators.
The IPO proceeds will fund advancement of the company's therapeutic pipeline and support manufacturing scale-up—a critical component for gene-editing therapies, which face complex manufacturing challenges. The offering reflects confidence in Doudna's scientific track record and the broader maturation of CRISPR technology from research stage to clinical application. Individual stakeholders including Doudna herself benefit from the liquidity event, with her personal stake valued at approximately $8.5 million, while the UC Board of Regents' early-stage investment is valued at approximately $2.6 million, underscoring the commercial value creation from academic research foundations.
The IPO marks Scribe as the 14th biotech company to go public in 2026, reflecting a resurgence in biotech capital formation in the second half of the year and indicating institutional appetite for companies with differentiated platforms addressing significant medical needs, even at earlier stages of clinical development.
The company's clinical focus centers on CRISPR-based gene-editing treatments targeting cardiovascular risk factors, with initial therapeutic candidates designed to lower low-density lipoprotein cholesterol and triglycerides. This lipid-lowering focus represents a significant commercial opportunity within cardiovascular disease prevention, a market segment dominated by traditional pharmaceutical approaches. Scribe's platform approach to genetic medicine positions it distinctly within the expanding landscape of precision therapeutics.
Scribe Therapeutics has established substantial partnership infrastructure with established pharmaceutical giants, including collaborations with Biogen, Sanofi, and Eli Lilly. These partnerships represent over $180 million in combined funding commitments, providing both validation of the platform's scientific merit and significant capital resources to advance clinical development. Such partnerships also mitigate development risk by distributing financial and regulatory burdens across experienced pharmaceutical operators.
The IPO proceeds will fund advancement of the company's therapeutic pipeline and support manufacturing scale-up—a critical component for gene-editing therapies, which face complex manufacturing challenges. The offering reflects confidence in Doudna's scientific track record and the broader maturation of CRISPR technology from research stage to clinical application. Individual stakeholders including Doudna herself benefit from the liquidity event, with her personal stake valued at approximately $8.5 million, while the UC Board of Regents' early-stage investment is valued at approximately $2.6 million, underscoring the commercial value creation from academic research foundations.
The IPO marks Scribe as the 14th biotech company to go public in 2026, reflecting a resurgence in biotech capital formation in the second half of the year and indicating institutional appetite for companies with differentiated platforms addressing significant medical needs, even at earlier stages of clinical development.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.